{"id":45480,"date":"2022-06-24T15:01:46","date_gmt":"2022-06-24T13:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/"},"modified":"2022-06-24T15:01:46","modified_gmt":"2022-06-24T13:01:46","slug":"propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/","title":{"rendered":"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split"},"content":{"rendered":"
\n

\nCompany Filed a Definitive Information Statement Under Section 14C of the Exchange Act<\/i>\n<\/p>\n

MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc.<\/b><\/a> (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company filed a Definitive Information Statement under Section 14C of the Exchange Act on June 9, 2022, to increase the authorized shares of common stock and the option to effectuate a reverse split of common stock at the discretion of the Board. Mr. James Nathanielsz, BAS, MEI, CEO and Chairman at Propanc, believes the increase in authorized shares is necessary for the Company as a result of recent volatile market conditions, which have been broad and far reaching for microcap companies. Regarding the option for a reverse split of common stock, Mr. Nathanielsz does not foresee the Board proceeding in the near future due to a number of factors.\n<\/p>\n

<\/a><\/p>\n

\n\u201cVolatile market conditions as a result of recent global events have meant that CEO\u2019s of publicly listed Companies are navigating through unchartered waters. Propanc continues to remain proactive and will determine at the appropriate time if and when sufficient measures are needed to generate the best result for shareholders,\u201d said James Nathanielsz. \u201cMy team and I have been working on a long-term plan and vision which we will continue to strive towards despite recent challenging market conditions, and accept that whilst we work on our strategic plans, the market takes time to see these plans harness the right valuation for shareholders. We firmly believe we have put a solid foundation in place to achieve success with our lead product candidate, PRP, as we advance towards early-stage clinical development. We are exploring potential opportunities with strategic partners and clinical researchers to advance the Company\u2019s interests and will continue to provide timely market updates as we progress.\u201d\n<\/p>\n

\nPRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers.\n<\/p>\n

\nAbout Propanc Biopharma, Inc.<\/b>\n<\/p>\n

\nPropanc Biopharma, Inc. (the \u201cCompany\u201d) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com<\/a>.\n<\/p>\n

\nThe Company\u2019s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body\u2019s primary defense against cancer.\n<\/p>\n

\nTo view the Company\u2019s \u201cMechanism of Action\u201d video on its anti-cancer lead product candidate, PRP, please click on the following link: http:\/\/www.propanc.com\/news-media\/video<\/a>\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nAll statements other than statements of historical facts contained in this press release are \u201cforward-looking statements,\u201d which may often, but not always, be identified by the use of such words as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cwill likely result,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201ccontinue,\u201d \u201ctarget\u201d or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company\u2019s ability to continue as a going concern absent new debt or equity financings; the Company\u2019s current reliance on substantial debt financing that it is unable to repay in cash; the Company\u2019s ability to successfully remediate material weaknesses in its internal controls; the Company\u2019s ability to reach research and development milestones as planned and within proposed budgets; the Company\u2019s ability to control costs; the Company\u2019s ability to obtain adequate new financing on reasonable terms; the Company\u2019s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company\u2019s ability to obtain and maintain patent protection; the Company\u2019s ability to recruit employees and directors with accounting and finance expertise; the Company\u2019s dependence on third parties for services; the Company\u2019s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company\u2019s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http:\/\/www.sec.gov<\/a>. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations and Media:<\/b>
Mr. James Nathanielsz
\n
Propanc Biopharma, Inc.
\n
irteam@propanc.com<\/a>
+61-3-9882-0780\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Company Filed a Definitive Information Statement Under Section 14C of the Exchange Act MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company filed a Definitive Information Statement under Section 14C of the Exchange … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45480","6":"format-standard","7":"category-industry"},"yoast_head":"\nPropanc Biopharma Announces No Immediate Plans for Reverse Stock Split - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company Filed a Definitive Information Statement Under Section 14C of the Exchange Act MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company filed a Definitive Information Statement under Section 14C of the Exchange ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-24T13:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220624005111\/en\/719646\/21\/propanc-logo-update.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split\",\"datePublished\":\"2022-06-24T13:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/\"},\"wordCount\":819,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005111\\\/en\\\/719646\\\/21\\\/propanc-logo-update.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/\",\"name\":\"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005111\\\/en\\\/719646\\\/21\\\/propanc-logo-update.jpg\",\"datePublished\":\"2022-06-24T13:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005111\\\/en\\\/719646\\\/21\\\/propanc-logo-update.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220624005111\\\/en\\\/719646\\\/21\\\/propanc-logo-update.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/","og_locale":"en_US","og_type":"article","og_title":"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split - Pharma Trend","og_description":"Company Filed a Definitive Information Statement Under Section 14C of the Exchange Act MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company filed a Definitive Information Statement under Section 14C of the Exchange ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-24T13:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220624005111\/en\/719646\/21\/propanc-logo-update.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split","datePublished":"2022-06-24T13:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/"},"wordCount":819,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220624005111\/en\/719646\/21\/propanc-logo-update.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/","url":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/","name":"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220624005111\/en\/719646\/21\/propanc-logo-update.jpg","datePublished":"2022-06-24T13:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220624005111\/en\/719646\/21\/propanc-logo-update.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220624005111\/en\/719646\/21\/propanc-logo-update.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/propanc-biopharma-announces-no-immediate-plans-for-reverse-stock-split\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45480"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45480\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}